(Q50620456)

English

A risk model for severe anemia to select cancer patients for primary prophylaxis with epoetin alpha: a prospective randomized controlled trial of the ELYPSE study group.

scientific article published on 27 January 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/19174452

A risk model for severe anemia to select cancer patients for primary prophylaxis with epoetin alpha: a prospective randomized controlled trial of the ELYPSE study group. (English)

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/19174452

15

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/19174452

Philippe Debourdeau

object named as

P Debourdeau

5

0 references

Isabelle Ray-Coquard

1

object named as

I Ray-Coquard

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/19174452

author name string

S Dussart

2

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/19174452

C Goillot

3

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/19174452

D Mayeur

4

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/19174452

H Ghesquieres

6

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/19174452

T Bachelot

7

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/19174452

A Le Cesne

8

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/19174452

B Anglaret

9

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/19174452

C Agostini

10

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/19174452

J-P Guastalla

11

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/19174452

L Lancry

12

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/19174452

P Biron

13

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/19174452

F Desseigne

14

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/19174452

publication date

27 January 2009

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/19174452

Annals of Oncology

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/19174452

20

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/19174452

6

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/19174452

1105-1112

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/19174452

A systematic review and meta-analysis of the pharmacological treatment of cancer-related fatigue

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN750

21 January 2018

A comparative economic analysis of pegylated liposomal doxorubicin versus topotecan in ovarian cancer in the USA and the UK.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN750

21 January 2018

Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN750

21 January 2018

Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN750

21 January 2018

Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN750

21 January 2018

American Society of Clinical Oncology clinical practice guidelines: opportunities and challenges

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN750

21 January 2018

Effect of treatment with epoetin-beta on survival, tumour progression and thromboembolic events in patients with cancer: an updated meta-analysis of 12 randomised controlled studies including 2301 patients

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN750

21 January 2018

Identification of patients at risk for early death after conventional chemotherapy in solid tumours and lymphomas

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN750

21 January 2018

Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN750

21 January 2018

Lymphopenia: a new independent prognostic factor for survival in patients treated with whole brain radiotherapy for brain metastases from breast carcinoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN750

21 January 2018

Risk Model Predictive of Severe Anemia Requiring RBC Transfusion After Chemotherapy in Pediatric Solid Tumor Patients

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN750

21 January 2018

Identifiers

10.1093/ANNONC/MDN750

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/19174452

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/19174452

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50620456&oldid=2034405295"